AlloDx was founded in August 2018, focusing on the R&D of new-generation diagnostic technologies and their clinical translation, and is committed to providing customers with high-quality, multi-dimensional testing services and product solutions to support precision medicine, AI-assisted diagnosis, and health management. The group and its subsidiaries have successively been recognized as National High-Tech Enterprises and Ministry of Science and Technology Technology-Based SMEs, and have received support from multiple national science and technology programs including the Shanghai Technology-Based SME Innovation Fund and the Ministry of Science and Technology's 'Science and Technology Innovation 2030 — Major Project on Four Major Chronic Diseases.'
AlloDx has built a full-chain integrated innovative R&D platform from omics marker discovery, raw material and material research and development, reagent and equipment development, clinical research verification to artificial intelligence data analysis. The total laboratory area exceeds 2,300 square meters, covering multiple functional areas such as immunoassay, P2 laboratory, standardized PCR, cell culture and protein purification, and has independent third-party medical laboratory qualifications. The company has 18 core invention patents, 23 software copyrights, and has jointly published 27 SCI papers, with continuous fruitful scientific research results.
AlloDx attaches great importance to clinical collaboration and translation. Its core testing product—donor-derived cell-free DNA (dd-cfDNA) testing—is among the early dd-cfDNA testing products in China with independent intellectual property rights that has been marketed and clinically applied. Related research results have been repeatedly invited for presentation at American, European, and international organ transplant congresses, and have provided technical support for multiple national industry standards including the Expert Consensus on Clinical Application of Donor-Derived Cell-Free DNA Testing in Kidney Transplantation. This product is currently in clinical use at nearly 50 transplant centers in China.
AlloDx is now entering a new development cycle. The company will continue to uphold the philosophy of 'focusing on real clinical needs and adhering to underlying technology innovation,' fully leverage the synergy of AI and biotechnology, build a product matrix centered on data-driven, differentiated competitiveness, and continuously explore innovative paths in precision diagnostics and intelligent healthcare.
